Entrada Therapeutics, Inc. (TRDA) will announce topline results from Cohort 1 of its phase 1/2 clinical study of ENTR-601-44 in Duchenne muscular dystrophy on Thursday, May 7, 2026.
Duchenne muscular dystrophy is a rare disease caused by mutations in the DMD gene, which encodes for the dystrophin protein essential to maintaining the structural integrity and function of muscle cells.
Mutations in the DMD gene lead to inadequate dystrophin production, resulting in progressive loss of muscle strength, impacting mobility and causing heart or respiratory complications that contribute to high mortality rates.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.